The menopausal transition: Symptom management and health promotion
Pharmacists in community-based practice.
Universal program number: 0401-0000-13-010-H01-P
Activity type: Knowledge-based
To develop the pharmacist’s ability to counsel women and monitor safety in managing symptoms of menopause in both the typical and complex menopause transitions.
The pharmacist is likely to encounter women who lack an accurate understanding of the appropriate application and the actual benefits and risks of menopausal hormone therapy, or MHT. In 2012, on the 10th anniversary of the the Women’s Health Initiative, or WHI — a large, randomized, controlled trial of estrogen and progestogen supplementation initiated after completion of the menopause transition — 15 professional organizations issued a joint statement that incorporates the new data and provides concise recommendations for MHT use. The document specifically states that hormone therapy is an acceptable option for women up to age 59 years or within 10 years of the final menstrual period, or FMP, for the treatment of moderate to severe menopausal symptoms.5 This important update is now slowly impacting the public. The community pharmacist plays an essential role in patient education and monitoring of MHT use to optimize patient outcomes.
Upon completion of this program, the pharmacist should be able to:
- Explain the changes in reproductive hormone production and classify the stages of the menopausal transition according to the symptom profile.
- Apply menopausal stage and symptom specific guidelines to menopause symptom management.
- Predict how benefits and risks of menopause hormone therapy vary with hormone products, patient age and duration of use.
- Apply the new data and guidelines to individualized plans for management of menopausal symptoms in women with contraindications to estrogen or progestogen use or women with persistent menopausal symptoms.
- Employ appropriate counseling to patients with atypical menopausal transitions, such as early menopause or surgical menopause, in adapting the safety data generated for older women.
To obtain credit:
A minimum test score of 70% is needed to obtain credit. Submit your answers to the learning assessment questions online at DrugStoreNewsCE.com. Your statement of credit will be available through CPE Monitor located at NABP.net. To ensure transmission of credit hours to CPE Monitor, you must enter your correct e-PID number in your CE profile.
All customer service questions should be directed to (800) 933-9666.
If you are a paid enrollee, there is no cost to participate in this lesson. The fee for participants who are not enrolled is $13.95.
Drug Store News is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This CPE Activity is approved for pharmacists and is worth 2.0 contact hours (0.2 CEUs). The activity is available for CE credit through Sept. 25, 2016.
By Patricia Geraghty, MSN, RN, FNP-BC, WHNP, nurse practitioner at Muir Obstetrics and Gynecologic Medical Group, adjunct clinical faculty at Holy Names University
Patricia Geraghty and the DSN editorial and continuing education staff do not have any actual or potential conflicts of interest in relation to this lesson.
- 2.00 Pharmacist